IL140239A0 - Anti-angiogenic proteins and methods of use thereof - Google Patents

Anti-angiogenic proteins and methods of use thereof

Info

Publication number
IL140239A0
IL140239A0 IL14023999A IL14023999A IL140239A0 IL 140239 A0 IL140239 A0 IL 140239A0 IL 14023999 A IL14023999 A IL 14023999A IL 14023999 A IL14023999 A IL 14023999A IL 140239 A0 IL140239 A0 IL 140239A0
Authority
IL
Israel
Prior art keywords
methods
angiogenic proteins
angiogenic
proteins
Prior art date
Application number
IL14023999A
Other languages
English (en)
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of IL140239A0 publication Critical patent/IL140239A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
IL14023999A 1998-06-17 1999-06-17 Anti-angiogenic proteins and methods of use thereof IL140239A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8968998P 1998-06-17 1998-06-17
US12617599P 1999-03-25 1999-03-25
PCT/US1999/013737 WO1999065940A1 (en) 1998-06-17 1999-06-17 Anti-angiogenic proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
IL140239A0 true IL140239A0 (en) 2002-02-10

Family

ID=26780845

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14023999A IL140239A0 (en) 1998-06-17 1999-06-17 Anti-angiogenic proteins and methods of use thereof

Country Status (8)

Country Link
EP (1) EP1086129A1 (zh)
JP (3) JP2002517999A (zh)
KR (1) KR100682666B1 (zh)
CN (1) CN1309663A (zh)
AU (1) AU753249B2 (zh)
CA (1) CA2331332A1 (zh)
IL (1) IL140239A0 (zh)
WO (1) WO1999065940A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
CA2396235A1 (en) * 2000-01-07 2001-07-19 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
EP1171602A1 (en) * 2000-02-10 2002-01-16 ZymoGenetics, Inc. Anti-angiogenic intestinal peptides, zdint5
WO2002012281A2 (en) 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
DE60234163D1 (de) 2001-01-05 2009-12-10 Viromed Ltd Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti-angiogenes protein oder teile davon kodiert, enthalten
ATE491034T1 (de) * 2001-04-13 2010-12-15 Thompson Boyce Plant Res Verfahren und zusammensetzungen für stabile transgene pharmazeutika und ihre verwendung als kontrazeptiva
CN100447155C (zh) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白
CA2451942A1 (en) * 2001-07-27 2003-02-13 Munirathinam Sundaramoorthy Crystallized structure of type iv collagen nc1 domain hexamer
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
JP4843767B2 (ja) * 2005-08-31 2011-12-21 国立大学法人 岡山大学 がん細胞特異的遺伝子発現法を用いた血管新生阻害薬
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
CN101962404A (zh) * 2010-06-17 2011-02-02 中国热带农业科学院热带生物技术研究所 一种用于治疗血管瘤的蛋白质
US9290562B2 (en) * 2011-08-17 2016-03-22 The Regents Of The University Of Colorado Transferrin-tumstatin fusion protein and methods for producing and using the same
WO2014180288A1 (zh) * 2013-05-06 2014-11-13 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
CN111087477B (zh) * 2020-01-03 2021-10-08 四川大学华西医院 GBM-7S(α1)-NC1(α3)融合蛋白及其制备方法
CN113735966B (zh) * 2021-09-29 2022-11-01 陕西巨子生物技术有限公司 一种抗肿瘤重组胶原蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876332A (en) * 1987-10-08 1989-10-24 Regents Of The Univeristy Of Minnesota Polypeptides with type IV collagen activity
US5114840A (en) * 1989-07-07 1992-05-19 Karl Tryggvason Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen
US5354690A (en) * 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5082926A (en) * 1989-12-14 1992-01-21 Regents Of The University Of Minnesota Polypeptide with type iv collagen cell adhesion, spreading and motility activity
US5081031A (en) * 1989-12-14 1992-01-14 Regents Of The University Of Minnesota Synthetic polypeptide with type iv collagen activity
US5424408A (en) * 1990-11-30 1995-06-13 Yale University α-3 chain type IV collagen polynucleotides
US5731192A (en) * 1993-08-27 1998-03-24 Yale University Collagen COL4A6: gene, protein and method of detecting collagen deficiency
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions

Also Published As

Publication number Publication date
JP2008301823A (ja) 2008-12-18
AU4575599A (en) 2000-01-05
JP2008019271A (ja) 2008-01-31
KR100682666B1 (ko) 2007-02-15
AU753249B2 (en) 2002-10-10
JP2002517999A (ja) 2002-06-25
CA2331332A1 (en) 1999-12-23
CN1309663A (zh) 2001-08-22
EP1086129A1 (en) 2001-03-28
WO1999065940A1 (en) 1999-12-23
KR20010053018A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
IL140239A0 (en) Anti-angiogenic proteins and methods of use thereof
AU8079901A (en) Promyostatin peptides and methods of using same
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
EP1071706A4 (en) FAST DEGRADABLE GFP FUSION PROTEINS AND METHOD OF USE THEREOF
WO2003059257A8 (en) Anti-angiogenic proteins and fragmentsand methods of use thereof
AP2001002080A0 (en) Pilveriser and method of pulverising
AU1334602A (en) Osteopontin-coated surfaces and methods of use
GB9819898D0 (en) New vaccine and method of use
GB9804121D0 (en) Anti-angiogenic vaccines: materials and methods relating thereto
IL128570A0 (en) Protein kinases and uses thereof
HUP9800146A3 (en) Thalidomide-derivatives and use of them
AU3964499A (en) Agouti-related protein analogs and methods of use
HUP0102850A2 (hu) Eljárások és kompozíciók fehérje funkcióinak meghatározására és módosítóinak azonosítására
EP1142999A4 (en) PROTEIN AND ITS DNA
AU2002214598A1 (en) Claspin proteins and methods of use thereof
EP1141269A4 (en) SECRETED PROTEINS AND THEIR USE.
EP1111047A4 (en) NEW PROTEIN AND ITS DNA
GB9828346D0 (en) Protein and compositions containing it
EP1210111A4 (en) DNA OF GAMMA HERPESVIRUS AND METHODS OF USE THEREOF
PL342185A1 (en) Modified psilium and method of obtaining same
HUP0003403A3 (en) Proteins having insecticidal activities and method of use
GB0002559D0 (en) Virulencegene and protein and their use
GB9828712D0 (en) Glycosylphosphatidylinositol specific phospholipase d proteins and usues thereof
EP1227149A4 (en) New protein and its use
GB9828359D0 (en) Protein and compositions containing it